Next Phase Newsletter

A venture capital firm founded in 2020 is headquartered in Paris, France, with an additional office based in the USA. The firm is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tends to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements,and seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 2015, a firm is headquartered in Beijing, managing three venture capital funds in RMB with a total of 1,400M RMB (~200M USD); And is still raising a fund in U.S. dollars of 50M~100M USD, with the confirmed limited partners from well-known Chinese big pharma. The firm has 24 portfolio companies, and is open to investing globally in the angel to series B round, with a focus on series A round. For therapeutics, the firm is interested in pre-clinical to phase III, mainly the pre-clinical stage. For each fund, Alwin Capital selects 10-15 companies to invest, and each investment ranging from 10MM RMB (1,420,000 USD) to 40MM RMB (5,700,000 USD); the rest of the fund will be used to invest the future rounds of those selected companies to help them grow.

The firm has a general interest in the early-stage life science technology assets, including therapeutics, diagnostics, medical devices, and digital health, especially MRA, Gene diagnostics, AI in healthcare, cell/gene therapy. The firm prefers projects in novel developing areas, but has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm has no specific requirements for the Company & Management Team.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

The investment firm is a philanthropic venture firm established by a family office to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. The US-based firm makes 4-5 investments each year of approximately $1 million into privately-held companies worldwide at both the seed and early venture stages. The firm operates under an evergreen structure and has made 43 investments to date.

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), the firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm operates from many offices across the globe and has invested in hundreds of companies in a wide variety of sectors. Recently, the firm has been expanding their portfolio in the life science/healthcare sector, and is actively seeking early-stage opportunities. With over $1B AUM, the firm will typically invest up to $3M as an initial check, with a significant portion of their capital dedicated  to follow-on investments. The firm is open to global opportunities, with a focus on USA, Europe, and Asia.

The firm is interested in therapeutics, diagnostics, digital health, and life science tools. The firm’s interest areas also include industrial biotechnology, synthetic biology, and robotics. While the firm does not completely rule out medical device opportunities, they are not a priority for the firm. Within therapeutics, the firm will consider both single assets and platform technologies. In general, the firm is stage and indication agnostic.

The firm has no specific company or management team requirements and is open to working with all types of management teams. The firm can act as a lead, co-lead, or co-investor, and provides operational support for their portfolio companies to help them scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.